CLARIVATE PLC
No enriched coverage for $CLVT in the last 7 days.
Cornick Kenneth L. purchased 900,000 indirectly-held shares of CLARIVATE PLC (CLVT) at an average of $1.86 ($1.85–$1.86, $1.67M total) across 2 trades over 2026-08-06 to 2026-08-07.
PR Newswire compiled 13 July press releases, including Lilly’s Phase 3 retatrutide results, Kroger’s agreement to acquire Giant Eagle, Clarivate’s sale of its Life Sciences and Healthcare segment for $600 million, BOXABL’s business combination valuing it at $3.5 billion, and Garmin’s LiveScope 2 sonar launch. It also lists other product and corporate updates.
Clarivate Plc (NYSE:CLVT) said it expanded agentic AI capabilities across its Cortellis life sciences portfolio. The company claims the updates embed AI into existing workflows to speed drug discovery decisions, improve safety assessment via multi-agent intelligence, and accelerate competitive and portfolio analysis. Clarivate said the goal is reducing manual effort and improving decision making across the R&D lifecycle.
Recent CLVT coverage spans financial news, insider activity and corporate actions.
In the last 30 days, CLVT insiders filed 5 SEC Form 4 transactions — 2 purchases ($1.7M) and 3 sales ($4.8M). The most active reporter was Snyder Andrew Miles with 3 filings.
This is an insider open-market purchase, which can be read as modest bullish signaling, but it is not a fundamental catalyst like earnings or guidance.
Segment divestiture can refocus the portfolio and affect earnings mix, leverage, and capital allocation.
This is a product and platform expansion announcement that could support incremental demand for Clarivate’s life-sciences workflow offerings, but it lacks financial guidance or quantified traction.
This is an insider sale under a Form 4, not a company fundamental update. It may modestly affect near-term sentiment but is unlikely to change intrinsic valuation by itself.
CFO succession is a near-term governance and execution signal, with possible read-through to capital allocation and the planned Life Sciences & Healthcare divestiture.
alphai scores every news story that mentions CLVT with an AI model for sentiment and relevance, and aggregates insider trades from CLARIVATE PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cornick Kenneth L. purchased 900,000 indirectly-held shares of CLARIVATE PLC (CLVT) at an average of $1.86 ($1.85–$1.86, $1.67M total) across 2 trades over 2026-08-06 to 2026-08-07.
1 min readPR Newswire compiled 13 July press releases, including Lilly’s Phase 3 retatrutide results, Kroger’s agreement to acquire Giant Eagle, Clarivate’s sale of its Life Sciences and Healthcare segment for $600 million, BOXABL’s business combination valuing it at $3.5 billion, and Garmin’s LiveScope 2 sonar launch. It also lists other product and corporate updates.
7 min readClarivate Plc (NYSE:CLVT) said it expanded agentic AI capabilities across its Cortellis life sciences portfolio. The company claims the updates embed AI into existing workflows to speed drug discovery decisions, improve safety assessment via multi-agent intelligence, and accelerate competitive and portfolio analysis. Clarivate said the goal is reducing manual effort and improving decision making across the R&D lifecycle.
3 min readSnyder Andrew Miles sold 2,489,618 indirectly-held shares of CLARIVATE PLC (CLVT) at $1.94 ($4.83M total) across 3 trades on 2026-08-03.
2 min readClarivate Plc (NYSE: CLVT) appointed Michael Easton as Executive Vice President and CFO effective Aug. 8, 2026, succeeding Jonathan Collins. Easton will focus on accelerating growth, improving profitability, strengthening free cash flow, and disciplined capital allocation. The change coincides with Q2 2026 results and references a planned divestiture of its Life Sciences & Healthcare segment.
4 min readSimply Wall St reports Clarivate Plc (CLVT) appointed Michael Easton as CFO and Executive Vice President effective Aug. 8, 2026, after Jonathan Collins’ departure. Easton previously served as Chief Accounting Officer overseeing controllership, reporting, treasury and FP&A. The article links the change to Clarivate’s capital discipline and cites forecasts of $1.9B revenue and $142.7M earnings by 2029.
5 min readClarivate Plc (Q2 2026) discussed its Value Creation Plan to shift from transactional to recurring subscription revenue. It plans to divest the Life Sciences & Healthcare segment by year-end 2026, targeting about 92% recurring revenue pro forma. Management cited a $269m non-cash impairment, $70m one-time costs, and expects low-end FCF due to transaction and restructuring costs.
6 min readClarivate Plc reported a tranche update on its equity buyback plan announced Dec. 16, 2024. From Apr. 1, 2026 to Jun. 30, 2026 it repurchased 0 shares for $0 million. Cumulatively it has bought back 63,042,889 shares, or 9.41%, for $242.63 million.
2 min readClarivate Plc (NYSE: CLVT) filed an 8-K. CFO Jonathan Collins resigned effective Aug. 7, 2026. Clarivate appointed Michael Easton as Executive Vice President and CFO effective Aug. 8, 2026, with $600,000 base salary and 2027 equity grant targeted at $2.0M. Matthew Lisowski was appointed Chief Accounting Officer effective Aug. 8, 2026.
3 min readCLARIVATE PLC (CLVT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. clvt-20260724 0001764046 false 00-0000000 0001764046 2026-07-24 2026-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event
2 min read
